Sonoma Pharmaceuticals, Inc.
SNOA
$3.24
-$0.03-0.92%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.94M | 14.91M | 14.29M | 13.97M | 13.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.94M | 14.91M | 14.29M | 13.97M | 13.55M |
| Cost of Revenue | 10.56M | 9.29M | 8.82M | 8.95M | 8.33M |
| Gross Profit | 6.38M | 5.62M | 5.47M | 5.03M | 5.22M |
| SG&A Expenses | 7.49M | 7.32M | 7.36M | 7.68M | 7.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.06M | 18.54M | 18.00M | 18.44M | 17.82M |
| Operating Income | -3.12M | -3.63M | -3.71M | -4.46M | -4.28M |
| Income Before Tax | -3.42M | -3.15M | -2.91M | -3.74M | -3.74M |
| Income Tax Expenses | 59.00K | 403.00K | 550.00K | 10.00K | -56.00K |
| Earnings from Continuing Operations | -3.48 | -3.56 | -3.46 | -3.75 | -3.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.48M | -3.56M | -3.46M | -3.75M | -3.69M |
| EBIT | -3.12M | -3.63M | -3.71M | -4.46M | -4.28M |
| EBITDA | -2.98M | -3.50M | -3.57M | -4.32M | -4.12M |
| EPS Basic | -2.20 | -2.46 | -3.05 | -3.96 | -4.91 |
| Normalized Basic EPS | -1.35 | -1.35 | -1.61 | -2.51 | -3.18 |
| EPS Diluted | -2.20 | -2.46 | -3.05 | -3.96 | -4.91 |
| Normalized Diluted EPS | -1.35 | -1.35 | -1.61 | -2.51 | -3.18 |
| Average Basic Shares Outstanding | 6.36M | 5.75M | 4.96M | 4.12M | 3.20M |
| Average Diluted Shares Outstanding | 6.36M | 5.75M | 4.96M | 4.12M | 3.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |